Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure

Hawkridge, Adam M.; Heublein, Denise M.; Bergen, H. Robert; Cataliotti, Alessandro; Burnett, John C.; Muddiman, David C.

doi:10.1073/pnas.0508782102

Cited by 243 publications

(194 citation statements)

References 33 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…Mass spectrometry analyses showed only minute amounts of circulating BNP 1-32. BNP 1-32 is found in patients with advanced HF in only very low levels (14 ). In blood samples from HF patients multiple N-and C-truncated fragments of BNP are present such as BNP 1-32, BNP 3-32, BNP 4 -32, BNP 5-32, BNP 5-31, BNP 1-26, and BNP 1-25 (24 ).…”

Section: Degradation Fragments Of Bnp In Circulationmentioning

confidence: 99%

“…Of interest, in that study, glycosylation had no impact. In addition, assays specific to the amino terminus (amino acids [11][12][13][14][15][16][17] are less susceptible to BNP cleavage by neprilysin than epitopes specific for amino acids 14 -21. Currently it is not clear how BNP and NT-proBNP concentrations are affected by treatment with LCZ696 in different conditions.…”

Section: Analytics Of Natriuretic Peptide Assaysmentioning

confidence: 99%

“…It has been proposed as a biomarker of cardiac ischemia. Another peptide of the signal residue containing amino acid residues 16 -25 may be a biomarker of ischemia (14 ).…”

Section: Bnpmentioning

confidence: 99%

See 2 more Smart Citations

Natriuretic Peptides and Analytical Barriers

Vasile

Jaffe

2017

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND:The natriuretic peptide system is an endocrine, autocrine and paracrine system that plays an important role in the maintenance of cardiovascular homeostasis. Biomarkers based on these peptides are important diagnostic and prognostic tools for myocardial function.CONTENT: Although natriuretic peptides were discovered more than 2 decades ago, their intricate and complex biology is associated with important questions not yet elucidated. The diversity of circulating forms of natriuretic peptides, the distinct expression of these forms in particular patients, and the heterogeneity of heart failure forms, along with specific assay-related and preanalytic issues, cause assays to be poorly harmonized.

show abstract

Section: Degradation Fragments Of Bnp In Circulationmentioning

confidence: 99%

Section: Analytics Of Natriuretic Peptide Assaysmentioning

confidence: 99%

See 1 more Smart Citation

Natriuretic Peptides and Analytical Barriers

Vasile

Jaffe

2017

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…Somewhere in HF progression, natriuretic peptides may 'lose' their effect. Response attenuation has multiple potential contributions: increased natiuretic peptides degradation resulting from clearance receptors or neutral endopeptidase upregulation (Andreassi et al 2001, Knecht et al 2002; down-regulation of the natriuretic peptide receptor A (Tsutamoto et al 1993, Bryan et al 2007; second messenger -cGMP -response attenuation (Lourenco et al 2009), alternate processing after secretion and degradation into a multitude of less active forms (Hawkridge et al 2005, Liang et al 2007, Martinez-Rumayor et al 2008. Dipeptidyl-peptidase IV cleaves the functional and active BNP1-32 into the less active BNP3-32 form and has gained increasing attention has part of this alternate processing and inactivation of natriuretic peptides in HF (Brandt et al 2006, Lourenco et al 2013.…”

Section: Discussionmentioning

confidence: 99%

Prognostic prediction in acute heart failure patients with extreme BNP values

et al. 2017

View full text Add to dashboard Cite

Background: Some patients have good prognosis despite elevated B-type natriuretic peptide (BNP), while others have ominous outcome with low BNP. We aimed at characterising these groups of patients. Methods: We analysed patients prospectively included in an acute HF registry. Vital status within 1-year post discharge was ascertained. A receiver-operating characteristic curve was used to define discharge BNP cut-offs for 1-year death prediction. Among survivors, we compared patients with low and not-low BNP (cut-off 400 pg/mL); and among non-survivors those with high vs not-high BNP (cut-off 2000 pg/mL). In the specific subgroups of patients with low and high BNP, mortality predictors were assessed with multivariate Cox-regression analysis. Results: We studied 584 patients, median age 78 years, 62.5% had HF with reduced ejection fraction; and 199 (34.1%) died during the first year. Non-survivors were very homogeneous irrespective of BNP, survivors were substantially different. In patients discharged with BNP <400 pg/mL, increasing age independently predicted death; when BNP !2000 pg/mL death predictors were higher NYHA class, and non-use of evidence-based therapy. BNP was outcome associated in both groups. Conclusions: Different prognostic predictors may play a role in different BNP levels. We suggest that risk stratification in HF would probably be more accurate if made on top of BNP knowledge.

show abstract

“…Over the past decade a number of papers have been published on the development of methods for the quantification of BNP by mass spectrometry (MS) [10,[12][13][14][15][16]. Issues including the very low concentration of BNP in plasma, the difficulties associated with measuring large intact peptides by MS and poor stability of BNP in plasma (half-life of 22.6 min) have however limited their further development for application in clinical laboratories.…”

Section: Introductionmentioning

confidence: 99%

A candidate liquid chromatography mass spectrometry reference method for the quantification of the cardiac marker 1-32 B-type natriuretic peptide

Torma¹,

Groves²,

Biesenbruch³

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: B-type natriuretic peptide (BNP) is a 32 amino acid cardiac hormone routinely measured by immunoassays to diagnose heart failure. While it is reported that immunoassay results can vary up to 45%, no attempt of standardization and/or harmonization through the development of certified reference materials (CRMs) or reference measurement procedures (RMPs) has yet been carried out. Methods: B-type natriuretic peptide primary calibrator was quantified traceably to the International System of Units (SI) by both amino acid analysis and tryptic digestion. A method for the stabilization of BNP in plasma followed by protein precipitation, solid phase extraction (SPE) and liquid chromatography (LC) mass spectrometry (MS) was then developed and validated for the quantification of BNP at clinically relevant concentrations (15-150 fmol/g). Results: The candidate reference method was applied to the quantification of BNP in a number of samples from the UK NEQAS Cardiac Markers Scheme to demonstrate its applicability to generate reference values and to preliminary evaluate the commutability of a potential CRM. The

show abstract

Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure

Abstract: C-terminal brain (B-type) natriuretic peptide (BNP)-biomarkers ͉ electrospray ionization ͉ Fourier transform-ion cyclotron resonance MS ͉ immunoaffinity purification ͉ targeted proteomics

Cited by 243 publications

References 33 publications

Natriuretic Peptides and Analytical Barriers

Natriuretic Peptides and Analytical Barriers

Prognostic prediction in acute heart failure patients with extreme BNP values

A candidate liquid chromatography mass spectrometry reference method for the quantification of the cardiac marker 1-32 B-type natriuretic peptide

Contact Info

Product

Resources

About